India To Start Receiving Sputnik V Vaccine Shots This Quarter, Production In India To Start From July

India is set to receive Russian Vaccine Sputnik V stocks in this quarter, between April and Jun, which was granted emergency use authorisation (EUA) earlier this week on Monday, 12 April reports Times of India.

After Covishield and Covaxin, Sputnik V became the third Covid-19 vaccine to be used in the country.

As part of its contract with the Russian Direct Investment Fund (RDIF), Hyderabad-based Dr Reddy’s Laboratories (DRL) is expected to receive around 250 million doses of Sputnik V.

The vaccine is slated to be available in larger quantities in the July-September quarter once the Indian companies that have tied up with RDIF begin manufacturing in the country.

RDIF has agreements with Gland Pharma, Stelis Biopharma, Hetero Biopharma, Panacea Biotec, Virchow Biotech, and Shilpa Medicare to manufacture 850 million doses of Sputnik V in India.